Mon, Mar. 16, 3:23 PM
Nov. 6, 2014, 5:38 PM
Aug. 7, 2014, 8:53 AM
Nov. 12, 2013, 8:57 AM
Aug. 19, 2013, 12:47 PM
- KaloBios Pharmaceuticals (KBIO -2.3%) slips after its Q2 loss came in greater than Street expectations.
- The company attributes the loss to increased spending for clinical trial programs and higher SG&A expenses associated with being a public company.
- Contract revenues were $15K, down from the prior-year period's $2.99M.
May. 15, 2013, 7:54 AM
KBIO vs. ETF Alternatives
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.
Other News & PR